Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

Clinical Trial to evaluate the efficacy of immunotherapy in a subset of Hormonal Receptor-positive/HER2-negative advanced breast cancer pati… Ended

2023-508546-17-00 Pre and post-menopausal women with locally advanced or 2020-07-01
A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with pre… Ended

2024-517166-42-00 Diffuse large B-cell lymphoma (DLBCL) 2020-05-29
Study of combination of metronomic chemotherapy and reactivator of immune response in inflammatory breast cancer spread to the chest wall. Ended

2023-507365-26-00 Locally recurrent, inoperable, and/or metastatic inflam 2020-05-20
Double-blinded (treatment group unknown to physician and patient), randomised (treatment group allocated by chance) phase II trial on the ef… Ended

2023-507897-42-00 Prevention of oesophageal strictures in adult patients 2020-05-12
Thoracic Radiotherapy plus Durvalumab in Elderly and/or frail NSCLC stage III patients unfit for chemotherapy - Employing optimized (hypofra… Ended

2024-513948-28-00 unresectable stage III NSCLC (Non–small-cell lung cance 2020-05-08
A Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax alone or in Combination with Ruxolitinib in Subjects with Myelofibrosi… Ended

2023-507276-53-00 Myelofibrosis 2020-03-23
Study that evaluating the efficacy of lenvatinib in patients with locally advanced GIST after failure of imatinib and sunitinib Ended

2024-513984-22-00 Patients with metastatic GIST 2020-03-17
A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Ended

2024-519070-39-00 Metastatic non-clear cell renal cell carcinoma 2020-03-06
CONGRATS : COMBINATION OF NIVOLUMAB PLUS RELATLIMAB IN PATIENTS WITH ADVANCED OR METASTATIC SOFT-TISSUE SARCOMA: A PROOF-OF-CONCEPT RANDOMIZ… Ended

2023-509495-42-00 Adult participants with advanced unresectable or metast 2020-02-27
A Study to evaluate the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients with Previously … Ended

2023-507389-15-00 Advanced Melanoma 2020-02-26
An open label, long-term extension study to evaluate the safety and efficacy of CRN00808 in subjects with acromegaly (ACROBAT ADVANCE) Ended

2024-511921-75-00 Acromegaly 2020-02-19
TOPical sirolimus in linGUal microkystic lymphatic malformation Ended

2024-515955-39-01 Lingual microcystic lymphatic malformations (LMLMs) are 2020-02-04
Efficacy and safety of Cabozantinib in patients with hepatocellular carcinoma progressing on or intolerant to prior treatment with immune ch… Ended

2024-516972-14-00 Hepatocellular carcinoma 2020-01-30
Medical-scientific research into a new own skin graft product (EHSG-KF) Ended

2024-512188-29-00 Adults and adolescents with partial deep dermal and ful 2020-01-20
Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Reinduction and second stop of TKI with Ponatinib in CML in … Ended

2023-508993-27-00 Chronic myelogenous leukemia 2020-01-17
A study of belimumab in children with systemic lupus erythematosus (SLE) Ended

2023-509413-37-00 Systemic Lupus Erythematosus 2020-01-17
A Phase 2, single arm study on dacarbazine (DTIC) followed by immunotherapy re-challenge in unresectable or metastatic melanoma with primary… Ended

2024-517065-16-00 Melanoma 2020-01-13
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy Ended

2024-515892-36-00 C3 glomerulopathy 2020-01-01
This trial will evaluate the safety and efficacy of HepaStem compared to placebo in patients with a cirrhotic liver condition called Acute o… Ended

2022-500252-28-00 Cirrhotic patients who are hospitalized for Acute on ch 2019-12-17
Study to evaluate the safety and tolerability of ZW25 in combination with palbociclib plus fulvestrant Ended

2023-508135-30-00 Breast cancer patients including those with locally adv 2019-12-09
Long-term safety, tolerability, and efficacy of losmapimod treatment in subjects with FSHD Ended

2024-512732-30-00 Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) 2019-12-06
A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations Ended

2023-510301-18-00 Advanced solid tumors (other than Urothelial tumors), a 2019-12-05
Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinant… Ended

2024-513074-22-00 non-small cell lung cancer (NSCLC) of clinical stages I 2019-12-02
Tepotinib plus osimertinib in osimertinib-relapsed MET amplified NSCLC Ended

2024-512005-87-00 Lung Cancer 2019-11-07